ASGR2 ELISA kit
- Known as:
- ASGR2 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- DL-ASGR2-Hu
- Product Quantity:
- 96T
- Category:
- Elisa Kits
- Supplier:
- WDSTD
- Gene target:
- ASGR2 ELISA kit
Related genes to: ASGR2 ELISA kit
- Gene:
- ASGR2 NIH gene
- Name:
- asialoglycoprotein receptor 2
- Previous symbol:
- -
- Synonyms:
- CLEC4H2
- Chromosome:
- 17p13.1
- Locus Type:
- gene with protein product
- Date approved:
- 1988-05-24
- Date modifiied:
- 2016-10-05
Related products to: ASGR2 ELISA kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: ASGR2 ELISA kit
- Blood-based biomarkers discovered by machine learning often lack disease specificity and cross-population robustness for clinical applications. We describe a biomarker discovery strategy that exploits monocytes as circulating sentinels to amplify disease-perturbed signals in blood. This strategy leverages monocyteMINER, a mechanistic transcriptional regulatory network inferred from monocyte transcriptomes of 1,202 healthy individuals. As proof-of-concept, we uncovered a 31-gene atherosclerosis-perturbed network that underpins disease etiology, identifying diagnostic signatures for coronary artery disease (ARAP2, P2RY14, FKBP15) and acute myocardial infarction (SERPINA1, ASGR2). For tuberculosis (TB), monocyteMINER uncovered a 5-gene signature (MAS_TB_META5: ANKRD22, AIM2, VAMP5, GBP5, TGM2) from just 438 samples. MAS_TB_META5 outperformed 77 existing signatures across 18 cohorts (>4,400 patients, 12 countries), achieving WHO target product profile for high-sensitivity screening (including in advanced HIV patients), and predicting TB progression up to 5 years before diagnosis. Thus, our findings show that monocyteMINER offers a generalizable platform for discovering clinically actionable biomarkers for diverse diseases. - Source: PubMed
Publication date: 2026/07/06
Arrieta-Ortiz Mario LWu Wei-JuBaliga Nitin S - Current diagnostic and prognostic biomarkers for acute myocardial infarction (AMI) remain limited. Protein succinylation may provide novel biomarker candidates for AMI. - Source: PubMed
Publication date: 2026/06/25
Yu JieMa XuFang JingLiu YingyingWang CongShi ShuxiaWang KaileLi YunlunZhang Lei - Laevichaulis alte is a slug in the order Systellommatophora that evolved from aquatic ancestors and now faces strong challenges from desiccation, respiration on land, and novel pathogens. Its mucus is essential for water retention, locomotion, and defense. To link terrestrial adaptation with mucus biosynthesis, we generated a gap-free genome assembly of L. alte using PacBio HiFi reads, Oxford Nanopore ultra-long reads, and Hi-C data. The genome shows low heterozygosity and holocentromeric chromosomes. Functional metabolomics revealed marked metabolic shifts between L. alte and the closely related aquatic species Peronia verruculata. In L. alte, differential metabolites were enriched in lipid metabolism, immune regulation, and stress response pathways, consistent with life in a dry and microbe-rich terrestrial environment. Comparative genomics and transcriptomics identified candidate genes linked to mucus secretion and physiological adaptation, including VEGF, ASGR2, and COL6A6. Further analyses highlighted the vascular endothelial growth factor (VEGF) gene family as a key regulator connecting angiogenesis, tissue remodeling, and mucus production pathways in L. alte. Together, this gap-free genome and multi-omics dataset establish a molecular framework that links genomic innovation, mucus biology, and terrestrial adaptation in Systellommatophora, and they offer a basis for understanding ecological niche specialization in land molluscs. - Source: PubMed
Publication date: 2026/06/15
Wang GangHe ShaofangWang ZhongkaiPang AoboSun XiaoliLiu RongchenWang FangChen SisiBian ZhijuanWei DongchengWu LiuhanZhao SiyaoJi QiutingSun YiqiSun NiyingFujaya YushintaTang BopingTan KianannZhang DaizhenChen Lianfu - In glioblastoma, the strong immunosuppression of the tumor immune microenvironment fosters tumor aggressiveness and decreases the effectiveness of therapeutic interventions, including immunotherapies. An intricate network of connections among tumor cells, stroma and infiltrating immune cells sustains immunosuppression. Lectins are immunoregulatory glycan-binding receptors contributing to immunosuppression. Their targeting is proposed as an appealing strategy for anti-cancer therapy. In this work, network-based approaches were exploited to identify a lectin profile that could dissect the complexity of tumor-immunity interactions in glioblastoma. Differential co-expression analysis, employing TCGA, CGGA and GTEx databases (145, 133 and 255 samples, respectively), identified a cluster of novel C-type lectins, with ASGR2 and CLEC12A as principal hubs. Furthermore, TIMER2.0 analysis revealed that their expression was significantly associated with immunosuppressive cells. ASGR2 and CLEC12A expression was also validated by cytofluorimetric analysis on both tumor and liquid biopsies from 20 glioblastoma patients. We report that ASGR2 and CLEC12A C-type lectins are associated with tumor-infiltrating immunosuppressive myeloid subsets and discriminate patients' poor prognosis. These results suggest that C-type lectins may contribute to the immunosuppressive network sustained by infiltrating myeloid immune cells in GB, resulting in exploitable targets for therapeutic interventions. - Source: PubMed
Publication date: 2026/03/13
Pace AngelicaAlfano CaterinaD'Angelo LucaNapoletano ChiaraZizzari Ilaria GraziaSantoro AntonioNuti MariannaFarina LorenzoPetti ManuelaRughetti Aurelia - Systemic lupus erythematosus (SLE) and idiopathic pulmonary fibrosis (IPF) share immune-inflammatory features, yet their convergent peripheral-blood transcriptomic signatures remain incompletely defined. We sought to identify shared blood gene programs linking SLE and IPF, prioritize robust cross-disease markers, and evaluate parsimonious diagnostic models with experimental and external assessments. - Source: PubMed
Publication date: 2026/02/20
Pang LijunLi YunfeiChen JunjieShang ShuangshuangLi MingHuang Chuanbing